Prostate News

Prostate cancer testing petition open for signatures

Categories: Latest News,Medical,Prostate Matters

The Petition of Kristine Hayward Implement a funded, risk-based, equitable prostate cancer testing regime in NZ is now open for signatures.

The Petition Request: That the House of Representatives urge the Government to implement a centrally funded and administered risk-adapted early prostate cancer detection strategy based on prostate-specific (PSA) testing, risk calculators, and MRI imaging, and State-funded support for the psychological and physical effects.

The Petition Reason: Prostate cancer is the most commonly diagnosed cancer in New Zealand men. Over 3,500 are diagnosed each year and 650 die. Currently, I believe testing is unfunded, disorganised, and inequitable. I believe inequities in testing allow too many men to die, with Māori and rural men disproportionately affected. I believe we need a structured, population-based testing approach for early detection of prostate cancer in men over 50 (40 with a family history), just as we have with breast cancer.

If you would like to sign Kris’ petition please follow this link. We also encourage you to share it with others who may also wish to sign.

https://www.parliament.nz/en/pb/petitions/document/PET_116093/petition-of-kristine-hayward-implement-a-funded-risk-based

Background

  • The petition is intended to shift health professionals, Ministry of Health, and public thinking around the issue of the importance of a funded programme of regular testing for prostate cancer for men over 50 (40 with a family history); in a similar way to women aged between 45 and 69 years who can get a free mammogram every 2 years.
  • The petition is intended to building momentum toward a change in policy or in how testing for prostate cancer by PSA blood test and DRE are routinely offered to all age-appropriate men throughout NZ
  • This petition is intended to compel the Ministry of health to update its policies to require primary healthcare professionals to offer informed routine regular testing for prostate cancer via a PSA blood test and if indicated a DRE. AND to communicate these policies and expectations to primary healthcare providers.